Huntsman Corporation 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Huntsman Corporation and Huntsman International LLC for the event date of December 30, 2016. The report details the completion of a strategic asset disposition involving the Company's European surfactants manufacturing facilities.
Key Financial Metrics
The filing reports the following specific financial metric regarding the transaction:
- Transaction Enterprise Value: $225 million.
The filing text does not provide clear values for overall company revenue, profit, cash flow, margins, debt, or liquidity positions for the reporting period.
Material Changes
On December 30, 2016, Huntsman Investments (Netherlands) BV, a wholly-owned subsidiary of Huntsman Corporation, completed the sale of its European surfactants manufacturing facilities and related assets. The buyer was Innospec International LTD, a wholly-owned subsidiary of Innospec Inc. This transaction was executed pursuant to a Share and Asset Purchase Agreement originally dated October 25, 2016, and amended on December 22, 2016.
Outlook, Risks, and Contingencies
The agreement includes customary representations, warranties, and covenants. It provides for indemnification rights regarding breaches of these terms. The filing notes that the representations and warranties were made solely for the benefit of the contracting parties to allocate contractual risk and may be subject to standards of materiality differing from those applicable to investors. No specific forward-looking guidance or management commentary regarding future financial performance is included in this specific filing.
Key Facts for Investor Verification
- Verify the final net proceeds from the $225 million enterprise value sale after accounting for transaction costs and debt assumptions.
- Confirm the impact of this asset divestiture on the Company's consolidated revenue and EBITDA for the 2016 fiscal year.
- Review the attached Amended and Restated Share and Asset Purchase Agreement (Exhibit 2.1) for specific indemnification caps and holdback provisions.
- Assess the strategic rationale for exiting the European surfactants manufacturing segment as disclosed in the accompanying press release (Exhibit 99.1).